The Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145
Kancera reports that patient enrollment to the FRACTAL-study is completed and that top line results will be presented in Q3 2023
Kancera reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study and that Dr. Hanjing Xie has been appointed to Chief Medical Officer
Kancera provides operational update in connection with the interim report for the first quarter of 2022
Kancera’s drug candidate KAND145 effectively reduces tumor size in a preclinical model of ovarian cancer
